

## A Study on Seroprevalence of Measles IgM Antibody in Suspected Case of Measle in Tertiary Care Hospital Jamnagar

Dr. Saurabh Chhotalal Gamit<sup>1</sup>, Dr. Hitesh Kantibhai Shingala<sup>2\*</sup> Dr. Mala Sinha<sup>3</sup>

<sup>1</sup>Resident Doctor, Department of Microbiology, Shri M. P. Shah Medical College, Nehru Road, Guru Gobind Singh Hospital Campus, Indradeep Society, Jamnagar, Gujarat, India

<sup>2</sup>Associate Professor, Department of Microbiology, Shri M. P. Shah Medical College, Nehru Road, Guru Gobind Singh Hospital Campus, Indradeep Society, Jamnagar, Gujarat, India

### Original Research Article

\*Corresponding author  
Hitesh Kantilal Shingala

#### Article History

Received: 02.10.2018

Accepted: 07.10.2018

Published: 30.10.2018

#### DOI:

10.21276/sjpm.2018.3.10.13



**Abstract:** Measles virus belonging to the genus Morbillivirus in the family Paramyxoviridae. Measles virus is transmitted by aerosolized secretion deposit on upper respiratory tract mucosal surfaces. Measles is a highly infectious disease characterized by fever, respiratory symptoms, redness of eyes & maculopapular rash. The study was conducted in tertiary care hospital, Jamnagar. Children's 0-15 years of age with suspected case of measles symptoms like fever, cough, redness of eyes & maculopapular rash attending at Hospital which included in the study. Serum samples were screened for measles IgM by ELISA method. Out of 143 samples, total 18 (12.59%) were positive for measles IgM Ab. among this 10 (55.56%) male and 08 (44.44%) female and 13 (72.20%) were 0-5 years of age and 05 (27.80%) were 5-20 years of age. This study recognized age, nutritional status of children, socioeconomic status vaccination status of children as important demographic and risk factor of measles virus infection in children.

**Keywords:** Measles virus, Maculopapular rash, Aerosolized secretion, IgM, ELISA.

### INTRODUCTION

Measles virus (MV) is a single-stranded, negative-sense, enveloped (non-segmented) RNA virus of the genus Morbillivirus within the family Paramyxoviridae. Humans are the natural hosts of the virus; no animal reservoirs are known to exist. Measles is a highly contagious infectious disease caused by the measles virus [1, 2]. Symptoms usually develop 10–12 days after exposure to an infected person and last 7–10 days [3, 4].

Initial symptoms typically include fever, often greater than 40 °C (104.0 °F), cough, runny nose, and inflamed eyes [5]. Small white spots known as Koplik's spots may form inside the mouth two or three days after the start of symptoms [5]. A red, flat rash which usually starts on the face and then spreads to the rest of the body typically begins three to five days after the start of symptoms. Measles virus is transmitted via the respiratory route and causes systemic disease. MV enters the host by infection of alveolar macrophages and/or dendritic cells in the airways and is amplified in local lymphoid tissues. Systemic infection occurs with the respiratory epithelium of the nasopharynx as the primary site of infection. After the invasion and replication in the respiratory epithelium and regional lymph nodes for about 2 to 3 days, a primary viremia occurs with subsequent infection of the reticuloendothelial system, there is a further viral replication in regional and distal reticuloendothelial sites. A second viremia is said to occur 5-7 days after the initial infection. During the second viremia, there may be infection of the respiratory tract and other

organs. Measles virus is shedded from the nasopharynx starting with the prodrome until 3-4 days after rash onset. Despite the availability of an effective live attenuated vaccine, measles is still a severe problem with high morbidity and mortality rates primarily among children in developing countries. The major complications of measles are encephalitis, alveolobronchiolitis and otitis media. Encephalitis and alveolobronchiolitis are the major causes of death.

Measles is an airborne disease which spreads easily through the coughs and sneezes of infected people [3]. It may also be spread through contact with saliva or nasal secretions [3]. Nine out of ten people who are not immune and share living space with an infected person will catch it [9]. People are infectious to others from four days before to four days after the start of the rash [9]. Most people do not get the disease more than once. The measles vaccine is effective at preventing the disease, and is often delivered in combination with other vaccines [3]. Vaccination has resulted in a 75% decrease in deaths from measles

between 2000 and 2013, with about 85% of children worldwide being currently vaccinated [3]. Once a person has become infected, no specific treatment is available [3], but supportive care may improve outcomes [3]. This may include giving oral rehydration solution (slightly sweet and salty fluids), healthy food, and medications to control the fever [3, 7] Antibiotics may be used if a secondary bacterial infection such as pneumonia occurs [3]. Vitamin A supplementation is also recommended in the developing world [3].

Measles affects about 20 million people a year [1], primarily in the developing areas of Africa and Asia [6]. No other vaccine-preventable disease causes as many deaths [8]. In 1980, 2.6 million people died of it [6], and in 1990, 545,000 died; by 2014, global vaccination programs had reduced the number of deaths from measles to 73,000 [10, 11]. The risk of death among those infected is usually 0.2% [10], but may be up to 10% in people with malnutrition [6]. Most of those who die from the infection are less than five years old [6].

The classic symptoms include a four-day fever (the 4 D's) and the three C's—cough, coryza (head cold, fever, sneezing), and conjunctivitis (red eyes)-along with fever and rashes [12]. Fever is common and typically lasts for about one week; the fever seen with measles is often as high as 40 °C (104 °F) [13].

Koplik's spots seen inside the mouth are diagnostic for measles, but are temporary and therefore rarely seen [12]. Koplik's spots are small white spots that are commonly seen on the inside of the cheeks opposite the molars [14]. Recognizing these spots before a person reaches their maximum infectiousness can help reduce the spread of the disease [15].

The characteristic measles rash is classically described as a generalized red maculopapular rash that begins several days after the fever starts. It starts on the back of the ears and, after a few hours, spreads to the head and neck before spreading to cover most of the body, often causing itching. The measles rash appears two to four days after the initial symptoms and lasts for up to eight days. The rash is said to "stain", changing color from red to dark brown, before disappearing [16]. Overall, the disease from infection with the measles virus usually resolves after about three weeks [17].

Complications: Complications with measles are relatively common, ranging from mild complications such as diarrhea to serious complications such as pneumonia (either direct viral pneumonia or secondary bacterial pneumonia), bronchitis (either direct viral bronchitis or secondary bacterial bronchitis), otitis media [18], acute brain inflammation [19] (and very rarely SSPE—subacute sclerosing panencephalitis) [20], and corneal ulceration (leading to corneal scarring) [21].

A specific drug treatment for measles, ERDRP-0519 has shown promising results in animal studies, but has not yet been tested in humans [22, 23].

In India, measles was the major cause of mortality and morbidity in the pre-vaccination era. The major factors which determine the occurrence of the measles outbreak are, accumulation of the susceptible population, illiteracy, poor hygiene, low income, overcrowding and a refusal for vaccines [24]. The measles immunization coverage in India which ranged from 42.2-58.8%, suggested that there was a gradual increase in the coverage [25]. A nationwide coverage evaluation survey which was conducted by UNICEF in 2009-documented 74.1% and 78% measles immunization coverages among children who were aged 12-24 months in India and Gujarat respectively [26]. Because of the increase in the measles vaccine coverage, there is a reduction in the number of outbreaks and this has changed the epidemiological pattern which involves older children [27].

The new Strategic Plan presents a five-pronged strategy to cut global measles deaths by at least 95% by 2015 compared with 2000 levels and to achieve measles and rubella elimination in at least five WHO regions by 2020 [28]. The strategies include:

- High vaccination coverage;
- Monitoring spread of disease using laboratory-backed surveillance;
- Outbreak preparedness and response and measles case management;
- Communication and community engagement; and
- Research and development.

The member states of the United Nations have agreed to eliminate measles and rubella, and bring about an end to the associated deaths in newborns and children by 2030, and thus aid in the accomplishment of the Sustainable Development Goals [6]. In India, more than 2.5 million children acquire measles infection, while close to 49,000 infected children die each year, which in itself accounts for 37% of the disease-specific deaths worldwide [6]. The aim of the campaign is to reach more than 400 million children (aged 9 months to 15 years) in the next couple of years and administer a single shot of MR vaccine regardless of their earlier vaccine or disease status [6]. The plan is to provide the vaccine free of cost across the states in schools, health facilities, and in outreach sites [6].

## **MATERIALS AND METHODS**

### **Study area**

The study conducted in Microbiology laboratory of Tertiary Care Hospital, Jamnagar where samples of suspected measles patients from OPD, indoor patients, CHC and PHC of Jamnagar district. Total 143 blood sample were collected by venepuncture under aseptic precaution and centrifuge, the serum was

separated for investigation. The anti-measles virus IgM ELISA kit (Calbiotech Measles IgM ELISA) brought at room temperature for testing. Negative control, positive control, and calibrator are ready to use. Prepare 1:21 dilution of test samples, by adding 10 µl of the sample to 200 µl of sample diluent. Mix well. Dispense 100 µl of diluted sera, calibrator and controls into the appropriate wells. For the reagent, blank, dispense 100ul sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 20 minutes at room temperature. Remove liquid from all wells. Wash wells three times with 300 µl of 1X wash buffer. Blot on absorbance paper or paper towel. Dispense 100 µl of enzyme conjugate to each well and incubate for 20 minutes at room temperature. Remove enzyme conjugate from all


wells. Wash wells three times with 300 µl of 1X wash buffer. Blot on absorbance paper or paper towel. Dispense 100 µl of TMB substrate and incubate for 10 minutes at room temperature. Add 100 µl of stop solution. Read O.D. at 450 nm using ELISA reader within 15 min. A dual wavelength is recommended with reference filter of 600-650 nm.

**RESULTS AND DISCUSSION**

In this study total 143 serum samples of suspected case of measles virus infection, collected and processed for measles IgM antibody test. Total 18 samples found positive for measles IgM, so sero prevalence of Measles IgM antibody was 12.59% (Fig-1).

**Table-1:**

Total Samples	Positive	Seroprevalence
143	18	12.59%



**Fig-1:**

Out of 143 serum samples 85 was male and 58 were female. Out of total 85 males 10 were positive for

measles IgM antibody and out of 58 females 08 were positive for measles IgM antibody (Fig-2).

**Table-2:**

Sex	Total Samples (n= 143)	Positive (n=18)
Male	85	10
Female	58	08




**Fig-2:**

Among the total 143 serum samples 82 were belongs to 0-5 years of age and 61 were belongs to > 5 years of age. There were 13 positive cases for measles

IgM antibody from 0-5year age group and 05 positive cases from > 5 year of groups (Fig-3).

**Table-3:**

Age Group (In Years)	Total Samples (n=143)	Positive (n=18)
0-5	82	13
>5	61	05



**Fig-3:**

**CONCLUSIONS**

The finding of this study confirms that the presence of MV was more common in young age children (most of <5 years of age group) and in male patients in Jamnagar district during study period and still poses a public health problem, despite the availability of a safe and vaccine. Therefore, it is important for health providers and policy makers to recognize the health implications of this virus, review the vaccination age of infants, and intensity vaccination campaign programs.

**ACKNOWLEDGEMENT**

The author thanks to their colleagues, the faculty, the laboratory staff of the Microbiology Department for provision of reagents and technical advice. They are grateful for the cooperation of those patients who participated in this study.

**REFERENCES**

- Caserta, M. T. (2013). Measles, Merck Manual Professional.
- "Measles (Red Measles, Rubeola)". (2015). Department of Health, Saskatchewan. Archived from the Original on 10 February 2015.
- World Health Organization. Measles A fact sheet N286; 2015. Available from: target=" \_blank" href="http://www.who.int/mediacentre/factsheets/fs286/en/". [Last accessed on 2015 Nov 08]. Back to cited text, (1).
- Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., ... & Coggeshall, M. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The lancet*, 388(10053), 1459-1544.
- "Measles (Rubeola) Signs and Symptoms". cdc.gov. (2014). Archived from the original on 2 February 2015.
- World Health Organization. (2015). India's Measles-Rubella Vaccination Campaign a Big Step Towards Reducing Childhood Mortality, Addressing Birth Defects.
- Bope, E. T., & Kellerman, R. D. (2015). *Conn's current therapy 2016*. Elsevier Health Sciences.
- Kabra, S. K., & Lodha, R. (2013). Antibiotics for preventing complications in children with measles. *Cochrane Database of Systematic Reviews*, (8).
- Atkinson, W., Wolfe, C., & Hamborsky, J. (Eds.). (2011). *Epidemiology and prevention of vaccine-preventable diseases*. Public Health Foundation Publications.
- Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., ... & Coggeshall, M. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The lancet*, 388(10053), 1459-1544.
- Abubakar, I. I., Tillmann, T., & Banerjee, A. (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*, 385(9963), 117-171.
- Biesbroeck, L., & Sidbury, R. (2013). Viral exanthems: an update. *Dermatologic therapy*, 26(6), 433-438.
- Ludlow, M., McQuaid, S., Milner, D., de Swart, R. L., & Duprex, W. P. (2015). Pathological consequences of systemic measles virus infection. *The Journal of pathology*, 235(2), 253-265.

14. ^ a b c "Measles". Merck Manuals Professional Edition. January 2018. Retrieved 6 May 2018.
15. Baxby, D. (1997). The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucous membrane. *Reviews in medical virology*, 7(2), 71-74.
16. NHS UK: Symptoms of measles. Last reviewed: 26/01/2010 Archived 2011-01-31 at the Wayback Machine.
17. Ludlow, M., McQuaid, S., Milner, D., de Swart, R. L., & Duprex, W. P. (2015). Pathological consequences of systemic measles virus infection. *The Journal of pathology*, 235(2), 253-265.
18. Gardiner, W. T. (1924). Otitis media in measles. *The Journal of Laryngology & Otolaryngology*, 39(11), 614-617.
19. Fisher, D. L., Defres, S., & Solomon, T. (2014). Measles-induced encephalitis. *QJM: An International Journal of Medicine*, 108(3), 177-182.
20. Anlar, B. (2013). Subacute sclerosing panencephalitis and chronic viral encephalitis. In *Handbook of clinical neurology*, 112, 1183-1189. Elsevier.
21. Semba, R. D., & Bloem, M. W. (2004). Measles blindness. *Survey of ophthalmology*, 49(2), 243-255.
22. White, L. K., Yoon, J. J., Lee, J. K., Sun, A., Du, Y., Fu, H., ... & Plemper, R. K. (2007). Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. *Antimicrobial agents and chemotherapy*, 51(7), 2293-2303.
23. "The measles virus is highly infectious, but rarely deadly". (2017). NewScientist.com. Archived from the original on 5 February 2017.
24. Gupta, S. N., Vidya, R., Gupta, N., & Gupte, M. D. (2011). Factors precipitating outbreaks of measles in district Kangra of North India: A case-control study. *International Journal of Applied and Basic Medical Research*, 1(1), 24.
25. International Institute for Population Sciences. (2007). *India National Family Health Survey (NFHS-3), 2005-06* (Vol. 1). International Institute for Population Sciences.
26. UNICEF. (2009). Gujarat Factsheet. [www.unicef.org](http://www.unicef.org). Available from: [http://www.unicef.org/india/Gujarat\\_Factsheet.pdf](http://www.unicef.org/india/Gujarat_Factsheet.pdf). [accessed on April 1, 2012].
27. Helfand, R. F., Kim, D. K., Gary Jr, H. E., Edwards, G. L., Bisson, G. P., Papania, M. J., ... & Anderson, L. J. (1998). Nonclassic measles infections in an immune population exposed to measles during a college bus trip. *Journal of medical virology*, 56(4), 337-341.
28. WHO. (2012). Media centre. [www.who.in](http://www.who.in). Available from: [http://www.who.int/mediacentre/news/releases/2012/measles\\_20120424/en/index.html](http://www.who.int/mediacentre/news/releases/2012/measles_20120424/en/index.html). [accessed on May 10, 2012].